What is the clinical effect of dotalizumab (Jemperli)?

Dotalizumab (Jemperli) is an immunotherapy drug that has achieved significant clinical results in the treatment of ovarian cancer patients with highly unstable microsatellite mismatches (dMMR) or deficient DNA mismatch repair (dMMR). This article will discuss the clinical trial data of dotalizumab and its importance in the treatment of ovarian cancer.

The Challenge of Ovarian Cancer

Ovarian cancer is a malignant tumor that is usually diagnosed in late stages because early symptoms are not obvious. This makes the treatment of ovarian cancer more complicated because in the later stages, the cancer has spread to other tissues and organs, making surgery more difficult. Traditional cancer treatments, such as surgery, radiation therapy, and chemotherapy, may be effective against some types of ovarian cancer, but for some patients, the effectiveness is limited and may be accompanied by serious side effects.

Breakthrough in immunotherapy

Immunotherapy is an important breakthrough in cancer treatment. It harnesses the power of the immune system to attack and eliminate cancer cells. Dotalizumab is an anti-PD-1 immunotherapy drug. Its core principle is to enhance the immune system's attack on cancer cells by lifting the inhibition of PD-1 on T cells. In patients with ovarian cancer, particularly those with dMMR or dMSI-H signatures, dotalizumab has achieved encouraging clinical results.

Clinical trial data of dotalizumab

Here are some key clinical trial data on dotalizumab demonstrating its effectiveness in the treatment of ovarian cancer:

1. Phase II GARNETTrial:

GARNET is a pivotal multicenter clinical trial designed to evaluate the efficacy of dotalizumab indMMRor MSI-H efficacy in patients with ovarian cancer. The trial results are very encouraging:

Durable response rate: In theGARNET trial, a significant proportion of ovarian cancer patients treated with dolutelimumab showed durable anti-cancer responses, meaning their cancer continued to improve even after treatment ended.

Overall survival: Patients in the dotalizumab treatment group showed a significant advantage in overall survival, and they lived longer compared to traditional treatment.

Tolerability: In theGARNET trial, dotilizumab was relatively well tolerated, with most patients able to tolerate treatment and side effects effectively managed.

2. Practical clinical application:

The clinical application of dotalizumab has also been supported and recognized by many cancer treatment centers. Feedback from physicians and patients suggests that dotalizumab plays an important role in improving survival rates and quality of life for ovarian cancer patients.

3. Continuous research:

Studies of dolutelimumab are ongoing to further understand its effectiveness and potential side effects in different patient populations. In addition, researchers are also exploring the possibility of combining dotilizumab with other treatments, such as chemotherapy or other immunotherapies, to improve efficacy.

The future of dotalizumab

Clinical trial data of dotalizumab indicate that it has potentially significant efficacy in the treatment of ovarian cancer patients with highly unstable microsatellite mismatches (dMMR) or deficient DNA mismatch repair (dMMR). The emergence of this drug enriches the ovarian cancer treatment toolbox and provides patients with a new treatment option, especially for those patients who have failed or cannot tolerate traditional treatments. This drug represents a glimmer of hope.

However, it is important to note that every patient's condition is different and treatment plans should be developed on an individual basis. In addition, the use of dotalizumab may induce some side effects, such as immune-related inflammation, and therefore requires close monitoring and management. Taken together, dotalizumab represents an important advance in the field of immunotherapy, providing more hope and treatment options for ovarian cancer patients. Future research will continue to explore its potential in different cancer types and patient populations to further improve the effectiveness of cancer treatments.

Dotalizumab is not currently on the market in China, and it is not included in medical insurance. Patients cannot purchase it domestically and need to purchase dotalizumab through overseas channels. There are only original drugs available abroad, mainly from the United States, and the price is as high as about 50,000 yuan.